Table 1.
Characteristics and outcome measures of the included trials.
| Included studies | Study type | Number of participants | Mean age (years) | Female (%) | Treatment durations (weeks) | Intervention | Outcome measures | Depression type |
|---|---|---|---|---|---|---|---|---|
| Husain et al. (20) | DB | 40 | 35 | 20 (50%) | 12 | TAU + Minocycline 200 mg/d vs. TAU + Placebo | Score changes in HAMD-17 and CGI. Response (≥50% reduction in HAMD) Quality of life (EQ-5D) Remission (MADRS <9 points) | treatment-resistant depressive symptoms |
| Dean et al. (22) | DB | 71 | 49.42 | 47 (66.2%) | 12 | TAU + Minocycline 200 mg/d vs. TAU + Placebo | Scores changes in MADRS Response (≥50% reduction in HAMD) Quality of life (EQ-5D) | Major depression disorder |
| Emadi-Kouchak et al. (21) | DB | 46 | 35.53 | 16 (34.8%) | 6 | Minocycline 200 mg/d vs. Placebo | Score changes in HAMD-17; Response (≥50% reduction in HAMD); Partial response (25–50% reduction in HAMD) | Mild-to-moderate depression |
| Nettis et al. (18) | DB | 49 | 45.22 | 22 (56.4%) | 4 | TAU + Minocycline 200 mg/d vs. TAU + Placebo | Score changes in HAMD-17, BDI and CGI; Response (50% reduction in HAMD); Partial response (25% reduction in HAMD) | Treatment-resistant depression |
| Hellmann-Regen et al. (19) | DB | 168 | 46.09 | 79 (47%) | 6 | TAU + Minocycline 200 mg/d vs. TAU + Placebo | Score changes in HAMD-6, HAMD-17, MADRS, BDI and CGI Response (50% reduction of MADRS) Remission (MADRS <9 points) | Treatment-Resistant Depression |